5FX5
Novel inhibitors of human rhinovirus 3C protease
5FX5 の概要
| エントリーDOI | 10.2210/pdb5fx5/pdb |
| 関連するPDBエントリー | 5FX6 |
| 分子名称 | RHINOVIRUS 3C PROTEASE, GLYCEROL, TETRAETHYLENE GLYCOL, ... (6 entities in total) |
| 機能のキーワード | transferase |
| 由来する生物種 | HUMAN RHINOVIRUS 2 (HRV2) |
| 細胞内の位置 | Capsid protein VP0: Virion . Capsid protein VP4: Virion . Capsid protein VP2: Virion . Capsid protein VP3: Virion . Capsid protein VP1: Virion . Protein 2B: Host cytoplasmic vesicle membrane ; Peripheral membrane protein ; Cytoplasmic side . Protein 2C: Host cytoplasmic vesicle membrane ; Peripheral membrane protein ; Cytoplasmic side . Protein 3A: Host cytoplasmic vesicle membrane ; Peripheral membrane protein ; Cytoplasmic side . Protein 3AB: Host cytoplasmic vesicle membrane ; Peripheral membrane protein ; Cytoplasmic side . Viral protein genome-linked: Virion . Protease 3C: Host cytoplasm . Protein 3CD: Host cytoplasmic vesicle membrane ; Peripheral membrane protein ; Cytoplasmic side . RNA-directed RNA polymerase: Host cytoplasmic vesicle membrane ; Peripheral membrane protein ; Cytoplasmic side : P04936 |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 21264.09 |
| 構造登録者 | Kawatkar, S.,Ek, M.,Hoesch, V.,Gagnon, M.,Nilsson, E.,Lister, T.,Olsson, L.,Patel, J.,Yu, Q. (登録日: 2016-02-24, 公開日: 2016-06-22, 最終更新日: 2024-10-09) |
| 主引用文献 | Kawatkar, S.P.,Gagnon, M.,Hoesch, V.,Tiong-Yip, C.,Johnson, K.,Ek, M.,Nilsson, E.,Lister, T.,Olsson, L.,Patel, J.,Yu, Q. Design and Structure-Activity Relationships of Novel Inhibitors of Human Rhinovirus 3C Protease. Bioorg.Med.Chem.Lett., 26:3248-, 2016 Cited by PubMed Abstract: Human rhinovirus (HRV) is a primary cause of common cold and is linked to exacerbation of underlying respiratory diseases such as asthma and COPD. HRV 3C protease, which is responsible for cleavage of viral polyprotein in to proteins essential for viral life-cycle, represents an important target. We have designed proline- and azetidine-based analogues of Rupintrivir that target the P2 pocket of the binding site. Potency optimization, aided with X-ray crystallography and quantum mechanical calculations, led to compounds with activity against a broad spectrum of HRV serotypes. Altogether, these compounds represent alternative starting points to identify promising leads in our continual efforts to treat HRV infections. PubMed: 27265257DOI: 10.1016/J.BMCL.2016.05.066 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.7 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






